Grail (GRAL) Q3 2026 Earnings
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Q3 2026
EPS
-$2.21
est -$1.90
-16.4%
Revenue
$38M
est $44M
-15.1%
A double miss on earnings and revenue barely matters next to the FDA decision on Galleri expected by early Q1 2027, which would open the door to broad reimbursement. Galleri screening revenue still grew 14% in the meantime.
Mentioned: GRAL
Sponsored